Description: Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Enjingfu, a mouse nerve growth factor for injection; Anfulong, a recombinant human interferon a 2b injection; Jiefu, a recombinant human interferon a 2b spray; Bellafort, a combined hepatitis A and B vaccine; Anerlifu, a preservative-free influenza virus split vaccine; Paneraifu.1, an influenza A H1N1 vaccine; and Yierlifu, an inactivated enterovirus 71 vaccine. In addition, the company exports its products. Shandong Sinobioway Biomedicine Co., Ltd. was founded in 2000 and is based in Beijing, China.
Home Page: www.sinobiowaymed.com.cn
Peking University Biological City
Beijing,
100085
China
Phone:
86 10 8289 9370
Officers
Name | Title |
---|---|
Mr. Xiao Dan Tang | Exec. Chairman |
Mr. Jialin Yue | Co-GM & Director |
Mr. Shuhong Han | Gen. Mang. |
Mr. Bin Zhou | Financial Director |
Mr. Hui Zhao | Board Sec. |
Mr. Ren Yanshen | Co-Founder |
Mr. Chen Zhangliang | Co-Founder |
Ms. Wanling Wang | Deputy Gen. Mang. |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
GIC Sector: | Materials |
---|---|
GIC Group: | Materials |
GIC Industry: | Chemicals |
GIC Sub-Industry: | Diversified Chemicals |
Forward PE: | 0 |
---|---|
Trailing PE: | 66 |
Price-to-Book MRQ: | 4.5997 |
Price-to-Sales TTM: | 31.5442 |
IPO Date: | 2011-05-05 |
Fiscal Year End: | December |
Full Time Employees: | 653 |